Choose a language and wait for the translated text.
Under the new agreement, countries that choose to offer lenacapavir, a twice-yearly drug marketed as Yeztugo in the United States for HIV prevention, will be able to procure it through PAHO's regional purchasing system.
Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean | PharmaVoice
